Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decoglurant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.44 |
| ▸ | HPGD | P15428 | 9/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1348510 | 0.91 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL14827414 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL1346131 | 0.90 | LCK (0.43) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL1346398 | 0.90 | KDM4E (0.45) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL14850535 | 0.89 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL1349685 | 0.89 | LCK (0.40) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL1348819 | 0.89 | KDM4E (0.44) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL1347991 | 0.88 | LMNA (0.39) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL1349580 | 0.88 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL1346842 | 0.87 | CSNK2A1 (0.46) | KDM4EALDH1A1HPGDHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335430-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | UNIV YALE (US) | 2024-10-10 | — | — | US | claimed |
| US-20240033254-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | UNIV YALE (US) | 2024-02-01 | — | — | US | claimed |
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2023-06-15 | — | — | US | claimed |
| EP-4153549-A2 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Certego Therapeutics Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | Certego Therapeutics Inc. (US) | 2023-03-07 | — | — | US | claimed |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2022-04-28 | — | — | US | claimed |
| US-20210251969-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | YALE UNIVERSITY | 2021-08-19 | — | — | US | claimed |
| WO-2020041329-A1 | COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES | YALE UNIVERSITY (US) | 2020-02-27 | — | — | WO | claimed |
| JP-4801724-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| EP-1863818-B1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-03-10 | — | — | EP | claimed |
| EP-1863818-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-12 | — | — | EP | claimed |
| US-7238808-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | claimed |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-28 | — | — | US | claimed |
| WO-2006099972-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | claimed |
| EP-4676473-A2 | COMPOSITIONS AND METHODS FOR MODULATING STRESS AND USES THEREOF | Brightseed, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| US-20240335430-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | UNIV YALE (US) | 2024-10-10 | — | — | US | disclosed |
| US-7238808-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-09-28 | — | — | US | disclosed |
| WO-2006099972-A1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | KDM4E 354/4885ALDH1A1 1112/4885HPGD 320/4885 |
| US-20060217387-A1 | Acetylenyl-pyrazolo-pyrimidine derivatives | NAT1, TPMT, ACAT1 | KDM4E 1335/4885ALDH1A1 90/4885HPGD 347/4885 |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | KDM4E 354/4885ALDH1A1 1112/4885HPGD 320/4885 |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | GABRD, GABRA6, GABRA3 | KDM4E 354/4885ALDH1A1 1112/4885HPGD 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.